Ontology highlight
ABSTRACT: Background
Desoxycorticosterone pivalate (DOCP) is a commonly used mineralocorticoid replacement for dogs with primary hypoadrenocorticism (HA), but manufacturer-recommended dosing protocols can be cost-prohibitive. Recent reports also have raised concerns that label dose protocols could be excessive.Objective
To investigate the relative efficacy and adverse effects of 2 DOCP dosages in dogs with primary glucocorticoid and mineralocorticoid deficient HA.Animals
Thirty-seven dogs, including 19 test population dogs and 18 controls.Methods
Randomized controlled double-blinded clinical trial. Dogs with newly diagnosed primary HA were assigned to standard (2.2 mg/kg q30d, control population) or low-dose (1.1 mg/kg q30d, test population) DOCP treatment. Clinical a
SUBMITTER: Vincent AM
PROVIDER: S-EPMC8295656 | biostudies-literature | 2021 Jul
REPOSITORIES: biostudies-literature